Position in BIIB
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,181,773
+$383,673 QoQ
Shares Held
10,098
+3.0% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#333
of 1,031 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BIIB Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026KENNEDY CAPITAL MANAGEMENT LLC holds $85,405,719 across 10 Drug Manufacturers - General names. BIIB ranks #8 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
17,324 | $20,778,927 | |
| 2 | ABBV |
AbbVie Inc.
|
64,782 | $16,301,742 | |
| 3 | JNJ |
Johnson & Johnson
|
53,762 | $13,653,935 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
90,643 | $11,451,836 | |
| 5 | MRK |
Merck & Co., Inc.
|
74,733 | $9,603,190 | |
| 6 | AZN |
Astrazeneca PLC
|
29,684 | $5,628,680 | |
| 7 | AMGN |
Amgen Inc
|
6,130 | $2,219,795 | |
| 8 | BIIB |
Biogen Inc.
This page
|
10,098 | $2,181,773 |
All Filings in BIIB
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,181,773 | 10,098 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,798,100 | 9,808 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,584,437 | 9,003 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,237,886 | 8,837 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $565,531 | 4,503 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $609,074 | 4,451 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $672,083 | 4,395 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $693,947 | 3,580 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $681,087 | 2,938 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $500,261 | 2,320 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||